This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Affitech Research as, Peregrine Pharmaceuticals, Inc.. Active years: 2011-2016.
Company Filing History:
3 out of 11 
3 out of 10 Years Active: 2011-2016
Title: Kyle Schlunegger: Innovator in Anti-VEGF Antibody Research
Introduction
Kyle Schlunegger is a notable inventor based in Mission Viejo, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of human antibodies that target vascular endothelial growth factor (VEGF). With a total of 3 patents, his work focuses on innovative methods for treating cancer and other angiogenic diseases.
Latest Patents
One of Kyle's latest patents involves anti-VEGF antibody compositions and methods. This invention discloses human antibodies that specifically inhibit VEGF binding to only one of the two primary VEGF receptors, VEGFR2. The antibodies effectively inhibit angiogenesis and induce tumor regression, while also improving safety due to their specificity. This invention provides new human antibody-based compositions, methods, and combined protocols for treating cancer and other angiogenic diseases. Additionally, advantageous immunoconjugate compositions and methods using these new VEGF-specific human antibodies are also included in his patent.
Career Highlights
Throughout his career, Kyle Schlunegger has worked with several prominent companies in the biotechnology sector. He has been associated with Affitech Research and Peregrine Pharmaceuticals, Inc., where he has contributed to groundbreaking research and development in antibody therapies.
Collaborations
Kyle has collaborated with various professionals in his field, including his coworker Anita Kavlie, who is also a woman. Their joint efforts have further advanced the research and application of antibody-based treatments.
Conclusion
Kyle Schlunegger's innovative work in anti-VEGF antibody research has the potential to significantly impact cancer treatment and other angiogenic diseases. His contributions to biotechnology exemplify the importance of targeted therapies in modern medicine.